Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

about

Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.

P2860

Q47700032-B4F8B740-0D53-4D0D-85D3-A63B431547EC Q52626728-8C77F33B-37F5-414B-AA66-30659287C21F

P2860

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

Item

http://www.wikidata.org/entity/Q41835379

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Selective JAK3 Inhibitors with ...... ew Induced Fit Binding Pocket.

@en

type

Item

label

Selective JAK3 Inhibitors with ...... ew Induced Fit Binding Pocket.

@en

prefLabel

Selective JAK3 Inhibitors with ...... ew Induced Fit Binding Pocket.

@en

P1476

Selective JAK3 Inhibitors with ...... ew Induced Fit Binding Pocket.

@en

P2093

Cesear R Corona

http://www.w3.org/2001/XMLSchema#string

Ellen Pfaffenrot

http://www.w3.org/2001/XMLSchema#string

Julia Holstein

http://www.w3.org/2001/XMLSchema#string

Kamran Ghoreschi

http://www.w3.org/2001/XMLSchema#string

Matthew B Robers

http://www.w3.org/2001/XMLSchema#string

Michael Forster

http://www.w3.org/2001/XMLSchema#string

Silke M Bauer

http://www.w3.org/2001/XMLSchema#string

P2860

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Developing irreversible inhibitors of the protein kinase cysteinome

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6

Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

Covalent docking of large libraries for the discovery of chemical probes

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

P304

1335-1340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CHEMBIOL.2016.10.008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27840070

http://www.w3.org/2001/XMLSchema#string

P921

binding pocket

P932

5119931

http://www.w3.org/2001/XMLSchema#string

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

about

P2860

P2860

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932